The endothelin axis in cancer

被引:158
作者
Bagnato, Anna [1 ]
Rosano, Laura [1 ]
机构
[1] Regina Elena Inst Canc Res, I-00158 Rome, Italy
关键词
endothelin; endothelin receptor antagonist; G-protein-coupled receptor; antitumor therapy;
D O I
10.1016/j.biocel.2008.01.022
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The endothelin axis, comprising endothelins and their receptors, has recently emerged as relevant player in tumor growth and metastasis by regulating mitogenesis, cell survival, angiogenesis, bone remodeling, stimulation of nociceptor receptor, tumor-infiltrating immune cells, epithelial-to-mesenchymal transition, invasion and metastatic dissemination. Endothelin-1 participates in the growth and progression of a variety of tumors such as prostatic, ovarian, renal, pulmonary, colorectal, cervical, breast, bladder, endometrial carcinomas, Kaposi's sarcoma, brain tumors, melanoma, and bone metastases. This review highlights key signaling pathways activated by endothelin-1 axis in cancer, since the understanding the full spectrum activated by endothetin-1 is critical for the optimal design of targeted therapies. Preliminary experimental and clinical data demonstrate that interfering with endothelin receptor by using endothelin-1 receptor antagonists alone and in combination with cytotoxic drugs or molecular inhibitors could represent a new mechanism-based antitumor strategy. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1443 / 1451
页数:9
相关论文
共 27 条
[11]   Basic mechanisms responsible for osteolytic and osteoblastic bone metastases [J].
Guise, Theresa A. ;
Mohammad, Khalid S. ;
Clines, Gregory ;
Stebbins, Elizabeth G. ;
Wong, Darren H. ;
Higgins, Linda S. ;
Vessella, Robert ;
Corey, Eva ;
Padalecki, Susan ;
Suva, Larry ;
Chirgwin, John M. .
CLINICAL CANCER RESEARCH, 2006, 12 (20) :6213S-6216S
[12]  
Herrmann E, 2007, ONCOL REP, V18, P133
[13]   ZD4054, a potent, specific endothelin A receptor antagonist, improves overall survival in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer (HR-PC) and bone metastases [J].
James, N. D. ;
Borre, M. ;
Zonnenberg, B. ;
Beuzeboc, P. ;
Morris, T. ;
Phung, D. ;
Dawson, N. .
EJC SUPPLEMENTS, 2007, 5 (06) :3-3
[14]   A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma [J].
Kefford, Richard ;
Beith, Jane McNeil ;
Van Hazel, Guy Arthur ;
Millward, Michael ;
Trotter, James Marshall ;
Wyld, David Keith ;
Kusic, Rada ;
Shreeniwas, Revati ;
Morganti, Adele ;
Ballmer, Andrea ;
Segal, Eleonor ;
Nayler, Oliver ;
Clozel, Martine .
INVESTIGATIONAL NEW DRUGS, 2007, 25 (03) :247-252
[15]   Elevated plasma big ET-1 is associated with distant failure in patients with advanced-stage nasopharyngeal carcinoma [J].
Mai, HQ ;
Zeng, ZY ;
Zhang, CQ ;
Feng, KT ;
Guo, X ;
Mo, HY ;
Deng, MQ ;
Min, HQ ;
Hong, MH .
CANCER, 2006, 106 (07) :1548-1553
[16]   The endothelin family: An overview [J].
Masaki, T .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 35 :S3-S5
[17]   The endothelin axis: Emerging role in cancer [J].
Nelson, J ;
Bagnato, A ;
Battistini, B ;
Nisen, P .
NATURE REVIEWS CANCER, 2003, 3 (02) :110-116
[18]   Endothelin-1 promotes cell survival in renal cell carcinoma through the ETA receptor [J].
Pflug, Beth R. ;
Zheng, Hong ;
Udan, Michael S. ;
D'Antonio, Jason M. ;
Marshall, Fray F. ;
Brooks, James D. ;
Nelson, Joel B. .
CANCER LETTERS, 2007, 246 (1-2) :139-148
[19]   Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells [J].
Rosanò, L ;
Spinella, F ;
Di Castro, V ;
Nicotra, MR ;
Dedhar, S ;
de Herreros, AG ;
Natali, PG ;
Bagnato, A .
CANCER RESEARCH, 2005, 65 (24) :11649-11657
[20]   Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo [J].
Rosanò, L ;
Spinella, F ;
Di Castro, V ;
Nicotra, MR ;
Albini, A ;
Natali, PG ;
Bagnato, A .
AMERICAN JOURNAL OF PATHOLOGY, 2003, 163 (02) :753-762